The University of Chicago Header Logo

Connection

Hedy Kindler to Peritoneal Neoplasms

This is a "connection" page, showing publications Hedy Kindler has written about Peritoneal Neoplasms.
Connection Strength

2.627
  1. Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8.
    View in: PubMed
    Score: 0.345
  2. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
    View in: PubMed
    Score: 0.331
  3. Consensus guideline for the management of peritoneal mesothelioma. Cancer. 2025 Jul 01; 131(13):e35868.
    View in: PubMed
    Score: 0.205
  4. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005 Jun; 48(3):423-8.
    View in: PubMed
    Score: 0.200
  5. Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation. J Surg Oncol. 2025 Apr; 131(5):810-815.
    View in: PubMed
    Score: 0.197
  6. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786.
    View in: PubMed
    Score: 0.188
  7. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
    View in: PubMed
    Score: 0.184
  8. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer. 2023 07 15; 129(14):2152-2160.
    View in: PubMed
    Score: 0.176
  9. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol (NY). 2022 05; 47(5):1725-1740.
    View in: PubMed
    Score: 0.163
  10. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2021 02; 124(3):564-566.
    View in: PubMed
    Score: 0.148
  11. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021 02; 34(2):380-395.
    View in: PubMed
    Score: 0.148
  12. The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. J Oncol Pract. 2016 10; 12(10):936-937.
    View in: PubMed
    Score: 0.112
  13. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
    View in: PubMed
    Score: 0.074
  14. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006 Nov; 17(11):1615-9.
    View in: PubMed
    Score: 0.054
  15. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.052
  16. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.